<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01421433</url>
  </required_header>
  <id_info>
    <org_study_id>FQM 01/11</org_study_id>
    <nct_id>NCT01421433</nct_id>
  </id_info>
  <brief_title>A Comparative Study Between Lysine Clonixinate+Cyclobenzaprine and Caffeine+Carisoprodol+Sodium Diclofenac+Paracetamol</brief_title>
  <official_title>Non Inferiority,Phase III,Multicentric,Double Blind,Randomized,Parallel Study,Comparing Dolamin Flex (Lysine Clonixinate+Cyclobenzaprine) and Tandrilax(Caffeine +Carisoprodol+Diclofenac+Paracetamol)in Pain Reduction in Patients With Lumbago</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Farmoquimica S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmagenix Projetos em Medicina Farmacêutica Ltda.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Farmoquimica S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non inferiority, multicentric, double blind study whose the primary objective is to compare
      the effectiveness of two products in pain reduction. Primary endpoint: reduction in pain
      average at day 7 compared to day 1(baseline), using Analogue Visual Scale (AVS) for pain
      evaluation. Secondary endpoint: to evaluate the products safety at the gastrointestinal
      system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase IIIb, non-inferiority, multicentric, double-blind study.Population: 160 patients, 80 in
      each study arm, both gender with mild to moderate lumbago, without irradiation and with
      muscle contraction, aged 18 (eighteen) and 65 (sixty five) years, without previous history of
      stomach or duodenal ulcer and gastritis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">January 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain average reduction</measure>
    <time_frame>7 days</time_frame>
    <description>The metric that will be used is Pain Analog Visual Scale (PAVS), that it is a graphical representation with values 0-10.
To use the PAVS, the principal investigator should question the patient regarding their pain level, and the value 0 (zero) means no pain and the value 10 (ten) indicates the maximum pain level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of possible gastrointestinal effects</measure>
    <time_frame>7 days</time_frame>
    <description>The metric that will be used is checking the safety data reported by the patient in the Patient Diary and / or using data reported by patients by Phone Call.
A diary will be given for the patient, to make notes about possible gastrointestinal adverse events.
The principal investigator should call to the patient to know about possible gastrointestinal adverse effects of the drug.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Tandrilax</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reference product Intervention: Drug: Tandrilax (caffeine+carisoprodol+sodium diclofenac+paracetamol)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dolamin Flex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test product Intervention: Drug: Dolamin Flex (Lysine clonixinate and cyclobenzaprine)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tandrilax</intervention_name>
    <description>Tandrilax (caffeine, carisoprodol, sodium diclofenac, paracetamol). Tablets, administered 3 times a day, for 7 consecutive days.</description>
    <arm_group_label>Tandrilax</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolamin Flex</intervention_name>
    <description>Dolamin Flex (lysine clonixinate and cyclobenzaprine). Tablets, administered 3 times a day, for 7 consecutive days.</description>
    <arm_group_label>Dolamin Flex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed of the nature of the study and given written informed consent

          -  Patients with mild to moderate lumbago

          -  Aged between 18 and 65 years old

        Exclusion Criteria:

          -  Known allergy or sensitivity to drug components

          -  Treatment with another anti inflammatory or corticoid

          -  Treatment with oral anticoagulants

          -  Treatment with oxidase monoamine 2 weeks before the study

          -  Treatment with methotrexate

          -  Stomach or duodenal ulcer and gastritis

          -  Dehydration

          -  Acute myocardial infarction or heart failure

          -  Hyperthyroidism

          -  Pregnant or lactating patients

          -  Treatment with lithium

          -  User of alcohol and barbiturates

          -  Hepatic or renal failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rogerio T. Silva, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital São Luiz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital São Luiz</name>
      <address>
        <city>São Paulo</city>
        <zip>05673-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rogerio T. Silva</last_name>
      <phone>551181716767</phone>
      <email>rogerio@neo.org.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2011</study_first_submitted>
  <study_first_submitted_qc>August 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2011</study_first_posted>
  <last_update_submitted>March 7, 2012</last_update_submitted>
  <last_update_submitted_qc>March 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clonixin</keyword>
  <keyword>Anti-Inflammatory Agents, Non-Steroidal</keyword>
  <keyword>Cyclooxygenase Inhibitors</keyword>
  <keyword>Lysine</keyword>
  <keyword>L-Lysine</keyword>
  <keyword>Lysine Acetate</keyword>
  <keyword>Lysine Hydrochloride</keyword>
  <keyword>Amitriptyline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Amitriptyline</mesh_term>
    <mesh_term>Clonixin</mesh_term>
    <mesh_term>Cyclobenzaprine</mesh_term>
    <mesh_term>Carisoprodol</mesh_term>
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

